Seres Therapeutics (MCRB) Short Interest Ratio & Short Volume $0.92 -0.01 (-0.59%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Seres Therapeutics Short Interest DataSeres Therapeutics (MCRB) has a short interest of 17.38 million shares. This marks a 7.02% increase in short interest from the previous month. The short interest ratio (days to cover) is 4.5, indicating that it would take 4.5 days of the average trading volume of 4.24 million shares to cover all short positions.Current Short Interest17,380,000 sharesPrevious Short Interest16,240,000 sharesChange Vs. Previous Month+7.02%Dollar Volume Sold Short$17.03 millionShort Interest Ratio4.5 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares170,738,000 sharesPercentage of Shares Shorted10.18%Today's Trading Volume2,785,217 sharesAverage Trading Volume4,236,283 sharesToday's Volume Vs. Average66% Short Selling Seres Therapeutics? Sign up to receive the latest short interest report for Seres Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartMCRB Short Interest Over TimeMCRB Days to Cover Over TimeMCRB Percentage of Float Shorted Over Time Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Seres Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/202417,380,000 shares $17.03 million +7.0%N/A4.5 $0.98 11/15/202416,240,000 shares $8.93 million -9.0%N/A4 $0.55 10/31/202417,850,000 shares $14.63 million -1.1%N/A5 $0.82 10/15/202418,050,000 shares $14.72 million -3.3%N/A4.7 $0.82 9/30/202418,660,000 shares $17.65 million +8.4%N/A4.4 $0.95 9/15/202417,220,000 shares $17.21 million +8.0%N/A4.5 $1.00 Get the Latest News and Ratings for MCRB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/202415,940,000 shares $12.76 million -4.8%N/A4.2 $0.80 8/15/202416,750,000 shares $14.82 million +2.4%N/A4.3 $0.89 7/31/202416,360,000 shares $21.92 million -3.8%N/A3.7 $1.34 7/15/202417,000,000 shares $20.23 million -17.8%N/A3.4 $1.19 6/30/202420,690,000 shares $14.98 million -9.5%N/A4.3 $0.72 6/15/202422,850,000 shares $16.18 million +1.1%N/A4.9 $0.71 5/31/202422,600,000 shares $22.60 million -0.6%N/A4.5 $1.00 5/15/202422,740,000 shares $21.78 million +6.0%N/A4.7 $0.96 4/30/202421,460,000 shares $21.26 million +21.7%N/A4.6 $0.99 4/15/202417,630,000 shares $10.89 million -6.2%N/A4.4 $0.62 3/31/202418,800,000 shares $14.55 million +2.2%N/A4 $0.77 3/15/202418,400,000 shares $14.46 million +14.3%N/A3.9 $0.79 2/29/202416,100,000 shares $18.35 million +3.3%N/A3.3 $1.14 2/15/202415,590,000 shares $17.46 million No ChangeN/A3.5 $1.12 1/31/202415,590,000 shares $17.62 million -11.2%N/A3.4 $1.13 1/15/202417,550,000 shares $21.06 million +7.8%N/A3.3 $1.20 12/31/202316,280,000 shares $22.79 million -21.8%N/A3.3 $1.40 12/15/202320,810,000 shares $20.66 million -0.7%N/A5 $0.99 11/30/202320,950,000 shares $21.79 million -10.4%N/A6 $1.04 11/15/202323,370,000 shares $28.04 million +1.2%N/A6.8 $1.20 10/31/202323,100,000 shares $35.34 million +1.1%N/A7.3 $1.53 10/15/202322,850,000 shares $34.28 million +7.9%N/A9.3 $1.50 9/30/202321,170,000 shares $50.38 million +3.8%N/A10 $2.38 9/15/202320,400,000 shares $58.34 million +0.8%N/A9.6 $2.86 8/31/202320,230,000 shares $69.79 million -13.4%N/A8.5 $3.45 8/15/202323,350,000 shares $87.56 million +3.6%N/A9.3 $3.75 7/31/202322,550,000 shares $108.47 million +1.7%N/A8.5 $4.81 7/15/202322,180,000 shares $100.25 million -2.9%N/A6.4 $4.52 6/30/202322,830,000 shares $109.36 million +25.0%N/A6.3 $4.79 6/15/202318,260,000 shares $104.45 million +17.7%N/A5.2 $5.72 5/31/202315,520,000 shares $76.82 million +3.4%N/A5.1 $4.95 5/15/202315,010,000 shares $80.00 million +23.2%N/A5.4 $5.33 4/30/202312,180,000 shares $59.38 million +36.1%N/A4.9 $4.88 4/15/20238,950,000 shares $52.45 million +3.4%N/A6.2 $5.86Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover 3/31/20238,660,000 shares $49.10 million -7.0%N/A8.4 $5.67 3/15/20239,310,000 shares $54.00 million +19.1%N/A10.5 $5.80 2/28/20237,820,000 shares $39.49 million +8.9%N/A9.9 $5.05 2/15/20237,180,000 shares $36.83 million +9.6%N/A9.9 $5.13 1/31/20236,550,000 shares $35.83 million -0.3%N/A8.9 $5.47 1/15/20236,570,000 shares $36.00 million -3.5%N/A8.2 $5.48 12/30/20226,810,000 shares $38.14 million +43.7%N/A8.5 $5.60 12/15/20224,740,000 shares $27.68 million +11.3%N/A5.7 $5.84 11/30/20224,260,000 shares $27.69 million -1.6%N/A4.4 $6.50 11/15/20224,330,000 shares $30.92 million -9.2%N/A4.4 $7.14 10/31/20224,770,000 shares $42.26 million -3.4%N/A4.8 $8.86 10/15/20224,940,000 shares $33.94 million +0.2%N/A4.9 $6.87 9/30/20224,930,000 shares $31.65 million +45.9%N/A4.7 $6.42 9/15/20223,380,000 shares $24.23 million -1.2%N/A3 $7.17 8/31/20223,420,000 shares $17.58 million +5.2%N/A3 $5.14 8/15/20223,250,000 shares $18.49 million -12.6%3.8%2.8 $5.69 7/31/20223,720,000 shares $15.29 million +4.8%4.6%3 $4.11 7/15/20223,550,000 shares $12.82 million -5.6%4.4%3.1 $3.61 6/30/20223,760,000 shares $12.90 million -25.0%4.6%3.5 $3.43 6/15/20225,010,000 shares $14.13 million +5.7%7.2%5.1 $2.82 5/31/20224,740,000 shares $14.69 million -5.4%6.8%5.6 $3.10 5/15/20225,010,000 shares $18.99 million +0.4%7.2%6.5 $3.79 4/30/20224,990,000 shares $23.60 million +8.2%7.2%6.7 $4.73 4/15/20224,610,000 shares $28.03 million -0.4%6.6%6.1 $6.08 3/31/20224,630,000 shares $32.97 million -14.9%6.7%5.8 $7.12 3/15/20225,440,000 shares $37.37 million -0.4%7.8%6.2 $6.87 2/28/20225,460,000 shares $43.68 million -0.2%7.8%4.3 $8.00 2/15/20225,470,000 shares $46.17 million -1.1%7.9%3.6 $8.44 1/31/20225,530,000 shares $46.12 million -14.8%8.0%3 $8.34 1/15/20226,490,000 shares $52.18 million +9.8%9.3%3.5 $8.04 12/31/20215,910,000 shares $49.23 million -34.3%8.5%3.2 $8.33 12/15/20218,990,000 shares $78.48 million +7.8%12.9%4.7 $8.73 11/30/20218,340,000 shares $89.74 million -6.2%12.0%4.3 $10.76 11/15/20218,890,000 shares $69.43 million +2.0%12.8%4.8 $7.81 10/29/20218,720,000 shares $53.02 million +7.0%12.6%5.5 $6.08 10/15/20218,150,000 shares $51.43 million -10.4%11.8%4.7 $6.31 9/30/20219,100,000 shares $63.34 million +70.1%13.1%4.4 $6.96 9/15/20215,350,000 shares $33.97 million -15.9%7.7%2.5 $6.35 8/31/20216,360,000 shares $40.77 million -9.0%9.2%3.6 $6.41 8/13/20216,990,000 shares $46.48 million +6.1%10.2%4.7 $6.65 7/30/20216,590,000 shares $46.79 million +6.6%9.6%4.5 $7.10 7/15/20216,180,000 shares $125.27 million -2.1%9.0%5.1 $20.27 6/30/20216,310,000 shares $150.49 million -7.5%9.2%7.8 $23.85 6/15/20216,820,000 shares $136.81 million -1.6%9.9%8.7 $20.06 5/28/20216,930,000 shares $146.29 million -2.5%10.1%8.8 $21.11 5/14/20217,110,000 shares $146.89 million -9.5%10.3%7.7 $20.66 4/30/20217,860,000 shares $166.47 million -1.0%11.4%8.1 $21.18 4/15/20217,940,000 shares $163.96 million +1.2%11.6%8.1 $20.65 3/31/20217,850,000 shares $152.53 million +8.6%11.5%7.4 $19.43 3/15/20217,230,000 shares $154.51 million +10.2%10.6%6.2 $21.37Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover 2/26/20216,560,000 shares $123.26 million +10.1%9.6%5.8 $18.79 2/12/20215,960,000 shares $155.32 million -14.2%8.7%5.5 $26.06 1/29/20216,950,000 shares $166.17 million -5.2%10.2%6.6 $23.91 1/15/20217,330,000 shares $195.78 million +3.4%10.8%7.3 $26.71 12/31/20207,090,000 shares $186.11 million +56.2%10.4%7.6 $26.25 12/15/20204,540,000 shares $112.64 million -6.8%6.7%5.3 $24.81 11/30/20204,870,000 shares $141.28 million -3.9%7.3%6.4 $29.01 11/15/20205,070,000 shares $174.71 million +6.5%8.4%6.9 $34.46 10/30/20204,760,000 shares $142.13 million -7.9%8.2%4 $29.86 10/15/20205,170,000 shares $167.66 million +12.6%9.0%1.8 $32.43 9/30/20204,590,000 shares $129.94 million No Change7.9%1.6 $28.31 9/15/20204,590,000 shares $125.40 million -12.4%7.9%1.6 $27.32 8/31/20205,240,000 shares $138.81 million -25.5%9.1%1.8 $26.49 8/14/20207,030,000 shares $191.64 million -21.2%13.2%2.5 $27.26 7/31/20208,920,000 shares $33.36 million +16.3%19.6%3.9 $3.74 7/15/20207,670,000 shares $31.68 million +3.1%17.7%11.8 $4.13 6/30/20207,440,000 shares $34.74 million +6.1%17.1%13.2 $4.67 6/15/20207,010,000 shares $30.70 million +4.0%16.1%16 $4.38 5/29/20206,740,000 shares $37.00 million +8.7%15.7%16.9 $5.49 5/15/20206,200,000 shares $28.52 million +10.9%14.5%16.8 $4.60 4/30/20205,590,000 shares $21.86 million +9.6%13.1%17.4 $3.91 4/15/20205,100,000 shares $18.87 million +6.7%12.2%19.3 $3.70 3/31/20204,780,000 shares $17.35 million -7.9%11.4%18.8 $3.63 3/13/20205,187,600 shares $17.59 million +4.8%12.5%19.3 $3.39 2/28/20204,950,000 shares $16.83 million +2.3%12.0%22.9 $3.40 2/14/20204,840,000 shares $14.62 million +1.9%11.9%22.9 $3.02 1/31/20204,750,000 shares $16.96 million +3.3%11.6%22.7 $3.57 1/15/20204,600,000 shares $16.74 million +15.9%11.2%21.8 $3.64 12/31/20193,970,000 shares $12.43 million +6.7%9.7%19.8 $3.13 MCRB Short Interest - Frequently Asked Questions What is Seres Therapeutics' current short interest? Short interest is the volume of Seres Therapeutics shares that have been sold short but have not yet been covered or closed out. As of November 30th, traders have sold 17,380,000 shares of MCRB short. Learn More on Seres Therapeutics' current short interest. What is a good short interest ratio for Seres Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. MCRB shares currently have a short interest ratio of 4.0. Learn More on Seres Therapeutics's short interest ratio. Which institutional investors are shorting Seres Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Seres Therapeutics: Wolverine Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Seres Therapeutics' short interest increasing or decreasing? Seres Therapeutics saw a increase in short interest during the month of November. As of November 30th, there was short interest totaling 17,380,000 shares, an increase of 7.0% from the previous total of 16,240,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Seres Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Seres Therapeutics: ORIC Pharmaceuticals, Inc. (16.00%), Terns Pharmaceuticals, Inc. (8.67%), Tourmaline Bio, Inc. (10.84%), Phathom Pharmaceuticals, Inc. (20.55%), ProKidney Corp. (11.53%), Astria Therapeutics, Inc. (6.53%), Ginkgo Bioworks Holdings, Inc. (20.44%), Annexon, Inc. (6.97%), Humacyte, Inc. (19.60%), PureTech Health plc (0.09%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Seres Therapeutics stock? Short selling MCRB is an investing strategy that aims to generate trading profit from Seres Therapeutics as its price is falling. MCRB shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Seres Therapeutics? A short squeeze for Seres Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MCRB, which in turn drives the price of the stock up even further. How often is Seres Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MCRB, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies ORIC Pharmaceuticals Short Squeeze Terns Pharmaceuticals Short Squeeze Tourmaline Bio Short Squeeze Phathom Pharmaceuticals Short Squeeze ProKidney Short Squeeze Astria Therapeutics Short Squeeze Ginkgo Bioworks Short Squeeze Annexon Short Squeeze Humacyte Short Squeeze PureTech Health Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MCRB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
